Streamlining EHR Integration through Common Data Models for RWE

Electronic Health Records (EHRs) provide a vast source of real-world data (RWD), but differences in formats and terminologies across systems create integration challenges. Common Data Models (CDMs) offer a solution by providing standardized data structures that enable consistent analysis across institutions, regions, and platforms.

This guide explores how pharmaceutical professionals and clinical trial stakeholders can use CDMs to harmonize EHR data, facilitating reliable real-world evidence (RWE) generation for regulatory and scientific purposes.

Why Common Data Models Are Essential:

Inconsistent EHR formats across healthcare systems hinder large-scale observational studies. CDMs solve this problem by:

• Defining standard tables and fields (e.g., patient demographics, diagnoses, drug exposures)
• Ensuring uniform terminologies (e.g., SNOMED CT, LOINC, RxNorm)
• Enabling cross-database analytics with common logic
• Supporting reproducible research through aligned metadata

Whether working on safety studies or comparative effectiveness research, CDMs improve data quality and integrity, enhancing GMP compliance when observational results are used to support regulatory filings.

Key Common Data Models Used in EHR Integration:

Here are the most widely adopted CDMs in the pharma and research community:

1. OMOP (Observational Medical Outcomes Partnership):
   • Developed by the Observational Health Data Sciences and Informatics (OHDSI) collaborative
   • Captures clinical data in a person-centric format
   • Supports standardized vocabularies and cohort definitions
2. Sentinel Common Data Model:
   • Created by the U.S. FDA’s Sentinel Initiative
   • Focused on post-marketing safety surveillance
   • Includes robust privacy protections and distributed analytics
3. PCORnet CDM:
   • Developed by the Patient-Centered Outcomes Research Institute
   • Optimized for patient-centered outcomes and engagement studies
4. HL7 FHIR (Fast Healthcare Interoperability Resources):
   • Not a CDM in the traditional sense, but a data exchange standard
   • Enables real-time EHR integration via APIs
   • Increasingly used in dynamic RWE platforms

Steps to Implement a Common Data Model for EHR Integration:

To adopt a CDM in your real-world evidence program, follow these steps:

1. Choose a CDM: Based on study goals, regulatory alignment, and partner ecosystem.
2. Extract Data: From source EHRs in both structured and unstructured formats.
3. Transform and Map: Clean and normalize data using extract-transform-load (ETL) pipelines, aligning with the CDM structure.
4. Standardize Terminologies: Use tools like Usagi for OMOP to map local codes to global standards.
5. Validate Data Quality: Perform checks on completeness, consistency, and referential integrity.
6. Deploy Analytics Tools: Utilize cohort builders, statistical engines, and visualization dashboards compatible with the CDM.

For long-term success, integrate CDM workflows into your Pharma SOP templates for reproducibility and compliance.

Regulatory Acceptance of CDM-Based Evidence:

Global regulatory bodies increasingly recognize CDM-aligned evidence in submissions. For example:

• The USFDA accepts Sentinel CDM results in drug safety monitoring.
• The EMA leverages OMOP-standardized data in DARWIN EU for RWE analysis.
• Health Canada encourages structured data submissions to improve review efficiency.

Maintaining traceability from original EHR sources to CDM tables is critical for regulatory audits. Align with data provenance principles to ensure integrity.

Common Challenges and Solutions in CDM Adoption:

• Challenge: Mapping diverse data sources with incompatible formats
• Solution: Use ETL automation tools like WhiteRabbit and RabbitInAHat (OMOP) for structured mapping
• Challenge: Clinical terminologies vary by institution or country
• Solution: Leverage SNOMED CT crosswalks and LOINC/RxNorm mappings
• Challenge: Governance and access across multi-site collaborations
• Solution: Employ federated data models or distributed queries with privacy controls

Build competency by including CDM mapping training in your Pharma Validation programs to improve internal capacity.

Case Example: OMOP CDM in Oncology RWE

In an oncology real-world evidence study, a pharmaceutical sponsor mapped EHR data from five hospitals to the OMOP CDM. They used standardized definitions to:

• Identify eligible lung cancer patients
• Track treatment regimens and outcomes
• Evaluate progression-free survival across treatment cohorts

This enabled fast data extraction and consistent outcome definitions, accelerating the generation of real-world insights aligned with StabilityStudies.in protocols.

Best Practices for Long-Term Sustainability:

• Document your ETL pipelines and update them regularly as source EHRs evolve
• Use open-source CDM tools to avoid vendor lock-in
• Join communities like OHDSI or PCORnet to stay updated on CDM advancements
• Align with pharma regulatory compliance for traceable and auditable CDM processes
• Incorporate metadata standards to improve data discoverability and reusability

CDM maturity models are emerging to guide institutions through phased adoption. Early wins in pilot projects can build momentum for wider rollouts.

Conclusion: Building RWE Infrastructure through CDMs

As the demand for high-quality real-world evidence grows, integrating EHRs using common data models becomes indispensable. CDMs provide the structure, standardization, and scalability needed to transform raw EHR data into regulatory-grade evidence.

Whether leveraging OMOP, Sentinel, PCORnet, or HL7 FHIR, success lies in methodical implementation, rigorous validation, and strategic alignment with regulatory and scientific goals. With the right approach, CDMs can unlock the full potential of EHRs for next-generation evidence generation in pharmaceuticals.

How to Standardize EHR Data for Research in Pharma

Electronic Health Records (EHRs) have revolutionized how patient data is collected, stored, and analyzed. For pharmaceutical professionals and clinical researchers, leveraging EHR data for real-world evidence (RWE) studies demands a robust standardization process. Without consistent structures, vocabularies, and formats, EHR data is often incomplete, fragmented, and unsuitable for regulatory-grade research.

This tutorial walks you through the practical steps of EHR data standardization, covering terminologies, models, mapping techniques, and quality control measures. By implementing these practices, pharma professionals can produce harmonized datasets that meet both research rigor and GMP compliance.

Why Standardization of EHR Data Matters:

Raw EHR data comes from diverse sources—hospital systems, outpatient clinics, specialty centers, and labs. Each source may use different formats, terminologies, and data entry practices. Standardization ensures:

• Interoperability across systems
• Accuracy and comparability of patient records
• Compliance with regulatory submissions (e.g., FDA, EMA)
• Reliable analysis for outcomes, safety, and utilization
• Faster integration with claims data or registries

As per CDSCO guidelines, structured and traceable data is a must for observational studies and post-marketing surveillance.

Step 1: Select a Common Data Model (CDM)

The first step in standardizing EHR data is choosing a suitable common data model. CDMs provide a universal structure that organizes medical records across settings. Popular models in pharma include:

• OMOP CDM: Used widely for observational and RWE studies; supports standard vocabularies.
• PCORnet CDM: Optimized for patient-centered outcomes research.
• i2b2/ACT: Often used for clinical cohort discovery.

For most pharma research applications, OMOP CDM is preferred due to its extensive use of controlled vocabularies and support from OHDSI (Observational Health Data Sciences and Informatics).

Step 2: Map EHR Data to Standard Vocabularies

Standard vocabularies ensure uniform interpretation of medical terms across institutions and systems. The key vocabularies include:

• SNOMED CT: Standard for clinical conditions and observations
• LOINC: Logical Observation Identifiers for lab tests and vitals
• RxNorm: Drug names and dosage forms
• ICD-10: Diagnosis coding for billing and analytics
• CPT/HCPCS: Procedure and service coding

Use mapping tools to align local terminologies with these standards. For example, map “high blood sugar” to SNOMED CT code 80394007 for “Hyperglycemia.”

Maintain documentation using Pharma SOP templates for mapping logs, version control, and quality checks.

Step 3: Normalize Field Formats and Units

Standardization also requires data field consistency. Normalize fields such as:

• Dates: Use ISO 8601 format (YYYY-MM-DD)
• Units: Convert lab results into standardized SI units
• Binary fields: Represent Yes/No as 1/0
• Sex: Use ‘M’ or ‘F’ or standard codes from HL7
• Vital signs: Specify measurement method (e.g., sitting BP vs ambulatory)

Normalize data types across tables (e.g., string, integer, boolean) to enable consistent queries and validation rules.

Step 4: Handle Missing or Ambiguous Data

Incomplete data is a frequent challenge in EHR research. Address this through:

• Imputation techniques (mean substitution, regression models)
• Logical inference (e.g., hospitalization dates from admission records)
• Flagging missing values for downstream sensitivity analysis
• Data source triangulation (e.g., match lab data with medication orders)

Document imputation methods in validation logs to ensure transparency in audits.

Step 5: Adopt Interoperability Standards

To ensure scalable and replicable integration across sites, use interoperability frameworks:

• HL7 FHIR: Fast Healthcare Interoperability Resources – supports API-based EHR access
• CDISC ODM: Clinical data exchange for trials and research
• X12/EDI: For linking insurance and claims data

HL7 FHIR, in particular, allows real-time access to normalized EHRs via endpoints—ideal for pharmacovigilance and post-market tracking.

Step 6: Quality Assurance of Standardized EHR Data

Ensure standardized data meets the following quality parameters:

1. Completeness: Are all required fields populated?
2. Accuracy: Are mappings and units verified?
3. Consistency: Are formats and types harmonized across records?
4. Traceability: Can source records be traced and reproduced?
5. Timeliness: Is the data up to date and refresh frequency defined?

Use automated data validation scripts and manual spot-checking. Include audits as part of pharma validation programs.

Use Case Example: RWE Study in Diabetes Patients

Suppose a pharma company wants to assess the effectiveness of a new diabetes drug in real-world patients using EHR data.

Steps taken:

1. Extract raw EHRs from three hospital systems
2. Normalize all lab results (HbA1c, glucose) into mg/dL
3. Map diagnosis codes to SNOMED CT and ICD-10 for diabetes and complications
4. Standardize drug prescriptions using RxNorm
5. Use OMOP CDM to align all fields
6. Validate data for completeness, duplicates, and logical errors
7. Link with claims data for hospitalization and cost tracking

The result: a research-ready dataset suitable for publication and submission to EMA.

Best Practices Summary:

• Select an industry-recognized CDM like OMOP
• Use controlled vocabularies for all medical terms
• Normalize units, data types, and field names
• Implement robust quality checks
• Maintain documentation and audit trails
• Train analysts on interoperability standards

Conclusion: Enabling RWE Through EHR Standardization

Without standardization, EHR data remains siloed and inconsistent. By applying the steps outlined here—adopting common data models, standard vocabularies, normalization protocols, and quality assurance—pharma professionals can convert disparate clinical records into powerful evidence generators.

Whether your goal is regulatory submission, safety signal detection, or comparative effectiveness research, harmonized EHR data forms the foundation of trustworthy and actionable insights. For advanced use cases like stability tracking or multi-source linkage, visit StabilityStudies.in.